Publication
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
Authors not recorded
Nat Med2024PMID 38710951PMC11186762stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugPemigatinibcivic_curation1.00
- geneFGFR1civic_curation1.00
- variantFGFR1 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 38710951
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR1 Amplification1 | ||||||||
| Pemigatinib | Malignant Breast Neoplasm | Predictive | C | Does Not Support Sensitivity Response | 3 | accepted | EID12542The phase 2 FIGHT-207 basket study was designed to evaluate pemigatinib, a selective FGFR inhibitor, in patients with previously treated advanced solid tumors harboring FGFR alterations. Eligible pati… (full text at CIViC) PMID 38710951 · Rodón et al., 2024 · Open in CIViC | civic |